Allergan (NYSE:ACT) & Pfizer (NYSE:PFE) On April 5, 2016 shares of Allergan had tumbled by 14.77% as investors had become skeptical that the deal with Pfizer would actually go through. The reason for investors becoming skeptical was because the government had implemented new tax inversion rules. Back in November Pfizer brokered a deal to buy … Read more
Amgen, Inc. (NASDAQ:AMGN) On October 28, 2015 Amgen had announced that it had received FDA approval for its skin cancer drug known as IMLYGIC. This drug is an injection type drug that helps boost the immune system to fight off and kill cancerous skin cells. This therapy only treats Melanoma — skin cancer– but does … Read more
Avalanche Biotech (NASDAQ:AAVL) Shares of Avalanche Biotech fell as much as 40% in after-hours trading on June 15, 2015 after the company announced results from its phase 2 wet-age related macular degeneration — wet-AMD — trial. The drop is huge but many investors should be assured that the drop was justified because the results were … Read more
Yesterday, was a pretty eventful day for Acadia Pharmaceuticals (ACAD). After canceling investor meetings, there was quite a bit of speculation that Allergan (AGN) would be taking over Acadia Pharmaceuticals (ACAD). As a result, the value of the stock climbed throughout most of the day. However, toward the end of the day, the company announced … Read more
Earlier today, I wrote about the fact that Acadia (ACAD) stock was rising high as investors speculated about a possible takeover by Allergan (AGN). The speculation was the result of delayed investor meetings and investors looking for reasons. However, it seems as though a reason has come to the table. Acadia (ACAD) announced that it … Read more
Zogenix (ZGNX) Produces A Loss For Q4 And Sells Zohydro Zogenix (ZGNX) recently announced that in Q4, the company lost more than $20 million. Also Zogenix (ZGNX) announced that it would be selling its Zohydro ER business to Pernix Therapeutics (PTX). The sale price on the business is $100 million, with an added $283.5 million … Read more
Valeant Pharmaceuticals (VRX) & Salix Pharmaceuticals (SLXP) Valeant Pharmaceuticals had agreed to buy Salix Pharmaceuticals for about $10.4 billion dollars in an all cash type deal. Valeant currently has many approved drugs in various areas such as: skin, eyes, and oral type drugs. This addition of Salix Pharmaceuticals will give Valeant access to a gastrointestinal … Read more